Vigil Neuroscience, Inc.
VIGL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | 50% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -5,531.2% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -5,272.3% | – |
| EPS Diluted | -0.56 | -0.49 | -0.57 | -0.47 |
| % Growth | -14.3% | 14% | -21.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |